Source:http://linkedlifedata.com/resource/pubmed/id/16085464
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2005-10-31
|
pubmed:abstractText |
alpha1-Antitrypsin (AAT) deficiency is a single-gene disorder in which a mutation in the AAT (approved symbol SERPINA1) gene (PI*Z) leads to misfolding of the protein, loss of the protective antiprotease effect of AAT for the lungs, and a toxic effect on hepatocytes. Optimal therapy for AAT deficiency will require a high percentage of hepatocyte transduction to be effective for liver and lung disease. Recently, rAAV genomes pseudotyped with capsids from serotypes 7 and 8 showed efficient hepatic transduction. We hypothesized that upon portal vein injection to target hepatocytes, serotype 8 would better transduce target cells and therefore express hAAT in both a greater percentage of cells and greater amounts. AAV2 and pseudotyped vectors for serotypes 1, 5, and 8 carrying the human AAT transgene were injected at 1 x 10(10) particle doses into C57Bl/6 mice. Circulating hAAT from AAV2/8-injected animals showed a 2-log advantage over AAV2 and 3-log increase over AAV2/1 and 5 for the 24-week study. Most significantly, up to 40% of total liver cells stained positive for the transgene in AAV2/8 subjects while remaining primarily episomal. Therefore, pseudotyped AAV8 provides a vehicle to infect a high percentage of hepatocytes stably and thereby express therapeutic molecules to modify AAT PiZ transcripts.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1525-0016
|
pubmed:author |
pubmed-author:Campbell-ThompsonMarthaM,
pubmed-author:ChoiYoung-KookYK,
pubmed-author:ClarkeTracyT,
pubmed-author:ConlonThomas JTJ,
pubmed-author:CossetteTravisT,
pubmed-author:CrawfordJamesJ,
pubmed-author:ErgerKirstenK,
pubmed-author:FlotteTerence RTR,
pubmed-author:Scott-JorgensenMardaM,
pubmed-author:SongSihongS
|
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
867-75
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:16085464-Animals,
pubmed-meshheading:16085464-Dependovirus,
pubmed-meshheading:16085464-Disease Models, Animal,
pubmed-meshheading:16085464-Female,
pubmed-meshheading:16085464-Gene Expression,
pubmed-meshheading:16085464-Gene Therapy,
pubmed-meshheading:16085464-Genetic Vectors,
pubmed-meshheading:16085464-Hepatocytes,
pubmed-meshheading:16085464-Humans,
pubmed-meshheading:16085464-Injections, Intravenous,
pubmed-meshheading:16085464-Mice,
pubmed-meshheading:16085464-Mice, Inbred C57BL,
pubmed-meshheading:16085464-Portal Vein,
pubmed-meshheading:16085464-Transgenes,
pubmed-meshheading:16085464-alpha 1-Antitrypsin,
pubmed-meshheading:16085464-alpha 1-Antitrypsin Deficiency
|
pubmed:year |
2005
|
pubmed:articleTitle |
Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
|
pubmed:affiliation |
Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, FL 32608, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|